Session Details

[D1-A3]Challenge for Junior bioanalysts

Wed. Mar 4, 2026 4:10 PM - 5:40 PM JST
Wed. Mar 4, 2026 7:10 AM - 8:40 AM UTC
Medium Hall(2nd Floor)
Chairman:Hitoshi Uchiyama(Towa Pharmaceutical Co., Ltd.), Tamiki Mori(Mediford Corporation)

[D1-A3-02]A Novel Method of Quantifying Multiple Monoclonal Antibodies utilizing LC-MS/MS and Antibody Engineering Technology: Application to Cassette-Dosing Pharmacokinetics

*Takuya Ichikawa1,3, Naoka Hironiwa2, Naoaki Murao1, Yuki Noguchi1, Keisuke Gotanda1, Nishiki Nagaya2, Taichi Kuramochi1, Toshiyuki Kudo3, Kiyomi Ito3 (1. Chugai Pharmaceutical Co., Ltd., 2. Chugai Pharmabody Research Pte. Ltd., 3. Musashino University)
Comment()

[D1-A3-03]Method development and application of a generic monkey ADA assay in the early development stage of antibody drugs

*Shio Maruyama1, Arisa Inoue1, Hiroko Shimada1, Hiroyuki Shimizu1 (1. Tanabe Pharma Corporation)
Comment()

[D1-A3-04]Evaluation of Ultra‑High‑Sensitivity PK/BM Assay Systems and Comparison of Measurement Platforms: Challenges and Approaches for Sensitivity Enhancement in PK/BM Assays

*Shunki Yasui1, Maiko Adachi1, Shiho Suruki1, Naomi Ootake1, Rena Watanabe1, Tamae Kimura1, Mayumi Hasegawa1, Kousuke Iijima1 (1. Kyowa Kirin Co., Ltd.)
Comment()

[D1-A3-05]Challenges in Flow Cytometry Biomarker Assessment from Non-Clinical to Clinical

*Satomi Sugiyama1 (1. Astellas Pharma Inc.)
Comment()